SCHEDULE: Khrom Capital Demands Acadia Strategic Review, Board Overhaul

Major shareholder Khrom Capital calls for Acadia Healthcare to initiate a formal strategic review, including a potential sale, citing persistent underperformance and governance failures.

Summary

• Khrom Capital, a significant shareholder owning approximately 5.5% of Acadia Healthcare Company, Inc.'s common stock, has sent a letter to the Board of Directors expressing deep concerns.
• The firm supports proposals outlined by Engine Capital LP, another activist shareholder, regarding governance enhancements and financial discipline.
• Khrom Capital demands that the Board immediately initiate a formal strategic review process, including the evaluation of a sale of all or part of the Company.
• The letter highlights Acadia's persistent underperformance, describing it as one of the worst-performing healthcare stocks of the past decade with a 'worst-in-class TSR'.
• Acadia's share price is drastically lower than it was ten years ago, while peers have created substantial shareholder value.
• The underperformance is attributed to repeated strategic missteps, entrenched and misaligned leadership, and governance failures, rather than industry dynamics or asset quality.
• Khrom Capital acquired its 5,037,448 shares for an aggregate purchase price of approximately $132.89 million, believing them to be undervalued.

Sentiment

Score: 2

Explanation: The filing is a highly critical activist letter from a major shareholder, detailing persistent underperformance, significant governance failures, strategic missteps, and a lack of accountability from Acadia's Board and management. It explicitly calls for urgent action, including a strategic review and potential sale, indicating severe dissatisfaction and a negative outlook on the current state of the company.

Positives

• The company's assets themselves remain valuable, indicating that the issues are related to management and governance rather than core business quality.
• The engagement of significant shareholders like Khrom Capital and Engine Capital could serve as a catalyst for necessary strategic and governance reforms, potentially unlocking shareholder value.

Negatives

• Acadia has been one of the worst-performing healthcare stocks of the past decade, with its share price drastically lower than ten years ago.
• The company has made a series of costly errors, including entering and then exiting the UK market, replacing a proven CEO with leadership that failed to generate value, and launching an aggressive and poorly justified $1+ billion capital expenditure campaign.
• Poor capital allocation decisions include repurchasing shares and raising leverage amid a significant capex cycle, a Department of Justice (DOJ) investigation, civil lawsuits, and negative free cash flow.
• Executive bonuses were awarded simply for enduring the DOJ probe, indicating misaligned incentives.
• The Board is criticized for being entrenched and misaligned, with several directors serving well over a decade (e.g., Reeve B. Waud for 20 years) without meaningful refreshment.
• Board and management collectively own only 1.3% of Acadia stock, demonstrating a lack of meaningful personal capital at risk and misalignment with shareholders.
• Governance failures include a staggered Board structure with de-staggering delayed until 2029, no policy on director tenure or age limits, and a lack of comprehensive corporate governance guidelines.
• Shareholders are disenfranchised as only the Board, not shareholders, may call special meetings.
• Recent annual meeting results showed significant 'Against' votes for Board nominees, including 3.3 million against Jason Bernhard, 8.8 million against William Grieco, 5.0 million against R. David Kelly, and 17.2 million against Reeve Waud, indicating a clear lack of confidence.

Risks

• Continued shareholder value destruction if the Board and management fail to address persistent underperformance and governance issues.
• The ongoing Department of Justice (DOJ) investigation and civil lawsuits pose legal and financial risks.
• Negative free cash flow could constrain financial flexibility and investment capacity.
• The Board's refusal to initiate a strategic review process could be considered negligent and a breach of fiduciary duties, potentially leading to further shareholder activism and legal challenges.
• Risk of continued entrenchment of the Board and management, hindering necessary reforms and value creation.

Future Outlook

Khrom Capital believes that a formal strategic review process, including the evaluation of a full or partial sale of the Company, represents the most efficient and effective path to unlocking shareholder value. They anticipate that credible and interested bidders exist. If the Board refuses to take meaningful action, Khrom Capital intends to pursue all available avenues, including nominating directors and building broader shareholder support to enforce accountability.

Management Comments

• "Shareholders deserve meaningful, urgent action to reverse Acadias trajectory as one of the worst-performing healthcare stocks of the past decade."
• "We believe that the Board must immediately initiate a formal strategic review process, including the evaluation of a sale of all or part of the Company."
• "The Boards fiduciary obligations require that it consider and evaluate in good faith all avenues for value creation for its shareholders."
• "We believe that the Board refusing to run a strategic review is, at best, negligentand at worst, a breach of its fiduciary duties."
• "This is not an asset quality problemit is a management and Board problem. The assets themselves remain valuable."
• "A Board so financially misaligned with its owners cannot be trusted to act with the urgency and accountability that shareholders deserve."
• "Excuses are no longer acceptablemeaningful action to create shareholder value must begin immediately."

Industry Context

Acadia Healthcare's persistent underperformance and 'worst-in-class TSR' over the past decade are explicitly contrasted with the substantial value creation by industry peers such as HCA Healthcare, Inc., Universal Health Services, Inc., and Tenet Healthcare Corp. This suggests that Acadia's challenges are company-specific, stemming from internal strategic and governance issues, rather than broader negative industry dynamics.

Comparison to Industry Standards

• Acadia's 'worst-in-class TSR' over the past decade contrasts sharply with substantial value creation by peers such as HCA Healthcare, Inc., Universal Health Services, Inc., and Tenet Healthcare Corp.
• The Board's lack of director tenure limits, age limits, and comprehensive corporate governance guidelines falls short of practices adopted by 'best-in-class boards' and 'most public companies'.
• The staggered Board structure, with de-staggering delayed until 2029, is deemed 'indefensible' compared to modern governance practices that prioritize shareholder accountability.

Management Changes

Corporate Governance

Legal Proceedings

• Ongoing Department of Justice (DOJ) investigation.
• Civil lawsuits.

Stakeholder Impact

• **Shareholders**: Currently suffering from persistent value destruction and underperformance. Potential for significant positive impact if the Board initiates a strategic review and implements governance reforms, leading to value unlocking. Conversely, continued underperformance and erosion of trust if the Board resists change.
• **Board and Management**: Under intense pressure from major shareholders, facing potential changes in composition, roles, or strategic direction. Their credibility and fiduciary performance are being publicly challenged.
• **Employees**: While not directly addressed, a strategic review or potential sale could lead to organizational restructuring, changes in leadership, or shifts in company culture, potentially impacting employee morale and job security.
• **Creditors**: The mention of raised leverage amid a capex cycle and negative free cash flow suggests potential concerns for creditors, though a strategic review or sale could also lead to debt restructuring or improved financial health.

Next Steps

• Khrom Capital calls on the Board to immediately announce a good-faith, public strategic review process, including the evaluation of a potential sale of the Company.
• They demand the acceleration of critical governance reforms, including de-staggering the Board well before 2029, implementing director age and tenure limits, and adopting comprehensive corporate governance guidelines.
• Khrom Capital states they will pursue all available avenues, including nominating directors and building broader shareholder support, if the Board refuses to take meaningful action.
• Operational improvements, such as those proposed by Engine Capital, are expected to continue in parallel with the strategic review.

Key Dates

Recommendation

The filing presents a highly critical assessment of Acadia Healthcare's persistent underperformance and significant governance failures, which have led to substantial shareholder value destruction. However, it also signals strong activist pressure from a major shareholder (Khrom Capital) demanding an immediate strategic review, including a potential sale, and accelerated governance reforms. This activist engagement creates a potential catalyst for value unlocking. A seasoned investor would likely 'hold' to observe the outcome of this activist campaign, as successful implementation of the demanded changes, particularly a sale, could lead to significant upside, despite the current poor operational and governance state of the company. The current state alone would warrant a 'sell', but the activist intervention introduces a speculative 'hold' for potential future gains.

Keywords

Acadia Healthcare, Shareholder Activism, Strategic Review, Corporate Governance, Khrom Capital, Engine Capital, Healthcare Services, Mental Health Facilities, Hospital Management, SEC Filing, Schedule 13D